Colorectal cancer (cancer that starts in the colon or rectum) is the third most commonly diagnosed cancer and the second leading cause of cancer death in the United States. There is a significant unmet need for improved therapies against this deadly disease – despite early detection increasing survival rates.
Mouse models resembling the biological situation are necessary in the evaluation of chemotherapeutic or immunotherapeutic agents against colon cancer. The murine colon adenocarcinoma cell line, MC-38, was used to create the MC-38 cell line-derived xenograft model, which is widely used to study the proliferation of colon cancer. Researchers at the National Cancer Institute (NCI) have developed a green fluorescent protein (GFP) expressing MC-38 cell line (MC-38-GFP) that allows for intravital imaging to evaluate anti-cancer agents in colon cancer.
The National Cancer Institute, Laboratory of Tumor Immunology and Biology, is seeking statements of capability or interest from parties interested in licensing this research material to evaluate anti-cancer agents in colon cancer.
- Use in preclinical studies to evaluate anti-cancer agents in colon cancer
- Biofluorescence allows for assessment of tumor progression after treatment with anti-cancer agents
- Intravital imaging allows for temporal and spatial assessment of tumor growth in real time
Jeffrey Schlom Ph.D. (NCI), John W. Greiner Ph.D. (NCI)
- Research Material: NIH will not pursue patent prosecution for this technology